Amendments to the specification:

On page 11, please delete the heading and first two paragraphs (lines 1-11) as shown below.

Short description of the drawings

[0001] Fig. 1 represents the influence of polymer's concentration on diclofenac sodium release when HPMC (Hypromellose), grades 4000 and 100, is used as a retardant material in the first region. The influence of lactose or dibasic calcium phosphate as a diluent is also shown. [0002] Fig. 2 represents an example of diclofenac release from bi-layered tablets, core tablets and mini-tablets formulations containing 75 mg diclofenac sodium and 200 µg misoprostol. The release of Voltaren retard 75 is shown for comparison.

On page 19, please amend lines 10-15 as show below.

The influence on the diclofenac sodium extended release of the concentration and grades of the Hypromellose 4000 mPa.s is shown in Figure 1 as is was noted, as was the use of dibasic calcium phosphate. The influence of the addition of 10% Hypromellose 100, 10% lactose or of 10% Dibasic Calcium phosphate is also shown was also noted.

On page 20, please amend lines 9-10 as show below.

[0003] Diclofenac sodium extended release is shown was shown and compared to a marketed product in figure 2.

On page 24, please amend lines 12-13 as shown below.

[0004] Diclofenac sodium extended release is shown was shown and compared to a marketed product in figure 2.